Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer

Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer

Introduction: Mirvetuximab soravtansine (MIRV) recently emerged as a promising therapeutic option for patients with platinum resistant ovarian cancer (PROC). In trials leading up to its approval, several ocular and other toxicities were identified. We report our experience with MIRV in a less-select...

Full description

Saved in:
Bibliographic Details
Main Authors: Susan M. Lang, Filippos Vingopoulos, Isabel Beshar, Sahana Somasegar, Elizabeth V. Adams, Simone A. Sasse, Talayeh Ghezelayagh, Emily Clair McClung, Amer Karam, Oliver Dorigo, Prithvi Mruthyunjaya, Babak Litkouhi
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Gynecologic Oncology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578925000633
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2352578925000633

Similar Items